Reviewer’s report
Title: 
Uterine choriocarcinoma coexistence with endometroid adenocacinoma
a case report and literature review
Version: 
0 
Date: 
25 May 2022
Reviewer: 
Ahmed El-Agwany
Reviewer's report:
Please include all comments for the authors in this box rather than uploading
your report as an attachment. Please only upload as attachments annotated
versions of manuscripts, graphs, supporting materials or other aspects of your
report which cannot be included in a text format.
Please overwrite this text when adding your comments to the authors.
Thank you for giving me the opportunity to review this intersecting article .
It is an interesting one that is reported a few in the literature .
There are some points to be considered, 
Kindly add the complaint , bhcg levels and final histopathology in the abstract
section .
You mentioned In the introduction that one case is reported in the introduction
but in the discussion, you mentioned 24 were reported ,kindly clarify 
is 
the patient sexually 
active
Does she receive treatment for the bleeding before Hysteroscopy 
kindly compare between ultraosund features before and after chemotherpay
regaridng site of mass, size , echogenicity , vascularity ,etc, bulging , myometrial
affection , staging based on imaging , cervical affection , nodal ones , vagina,….
Kindly add The Who score and figo stage of choriocsrcinoma and endometrial
cancer 
Pathology exam after surgery revealed no mass although you mentioned a mass
on ultrasound of 5cm before surgery .
The metastasis to the adenxa and nodes , it is endometrial or choriocarcinoma 
Ct was normal regarding these before surgery .
33 cycles of radiotherpay are for the endometrial 
cancer stage ?
Was the choriocsrcinoma deposits in the after hysterectomy , active or non active
?
What about Chemotherpay response score on pathology 
Was the chorci0carconoma and endometrial 
cancer separate on histopathology or
mixed .
Kindly add the site of each one on histopathology 
Was it synchronous primary or differentiated primary 
Regarding the references , kindly add correct numbering and add the recent case
presentations from the 24 cases .
Figure 3 , kindly add a fresh specimen , it is mentioned that no masses was
present although it was mentioned that a 5 cm mass was detected on ultraosund .
Publons Reviewer Recognition
. Springer Nature can send verification of this
review directly to Publons (a subsidiary of Clarivate Analytics). If you would
like to take advantage of this service, please click on the “Yes” option below.
Your name, email address, title of the reviewed manuscript, name of the journal,
and date of your review submission (the “Review Data”) will then be transmitted
to Publons after the final decision on the manuscript has been made. If you have
already registered at Publons, they will notify you of the receipt of this review
and update your profile 
as per your settings and their policy. If you are not
registered with Publons, you will receive an email from them asking you to
register in order for them to be able to recognize your review on your new
profile page. Publons may use the Review Data to generate derivative metadata
for the benefit of Publons and you as a reviewer, carefully considering the
sensitivity of such information. For example, Publons may verify your record as
a reviewer by updating your profile published on its webservice if you have
registered for such service or help editors to identify candidate reviewers. Please
find the details of processing in Publons’ privacy policy
https://publons.com/about/terms
Yes
Declaration of competing interests
Please complete a declaration of competing
interests, considering the following questions:
1
. 
Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially
from the publication of this manuscript, either now or in the future?
2
. 
Do you hold any stocks or shares in an organisation that may in any way
gain or lose financially from the publication of this manuscript, either now
or in the future?
3
. 
Do you hold or are you currently applying for any patents relating to the
content of the manuscript?
4
. 
Have you received reimbursements, fees, funding, or salary from an
organization that holds or has applied for patents relating to the content of
the manuscript?
5
. 
Do you have any other financial competing interests?
6
. 
Do you have any non-financial competing interests in relation to this
paper?
If you can answer no to all of the above, write 'I declare that I have no competing
interests' below. If your reply is yes to any, please give details below.
N/a
Reviewer Publication Consent.
 I agree for my report to be made available
under an Open Access Creative Commons CC-BY License (
http://creativecommons.org/licenses/by/4.0
) if this manuscript is accepted for
publication. Any comments that I do not wish to be included in the published
report have been included as confidential comments to the editor, which will not
be published.
If you are not happy for us to publish this report, please contact the
editorial office before completing the review.
If you wish, you can include your
name in your published report. Please note you must decide whether to include
your name at the start of the process and confirm this decision whenever
prompted. If you change your decision later, we will not be able to publish your
name.
I agree to the terms of the CC-BY 4.0 license; please publish my name with my
report.
Is the study design appropriate to answer the research question (including the use
of appropriate controls), and are the conclusions supported by the evidence
presented?
Yes
Are the methods sufficiently described to allow the study to be repeated?
Yes
Is the use of statistics and treatment of uncertainties appropriate?
Yes
Is the presentation of the work clear?
Yes
Are the images in this manuscript (including electrophoretic gels and blots) free
from apparent manipulation?
Yes